Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Analysts Set New Price Targets
Several equities research analysts have recently commented on OMCL shares. SVB Leerink started coverage on shares of Omnicell in a research report on Friday, July 15th. They set a "market perform" rating and a $124.00 price target for the company. Piper Sandler lowered their price target on shares of Omnicell from $162.00 to $150.00 and set an "overweight" rating for the company in a research report on Monday, August 8th. Wells Fargo & Company lowered their price target on shares of Omnicell from $188.00 to $158.00 and set an "overweight" rating for the company in a research report on Tuesday, May 3rd. TheStreet cut shares of Omnicell from a "b-" rating to a "c+" rating in a research report on Tuesday, May 17th. Finally, BTIG Research lowered their price target on shares of Omnicell from $190.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, July 27th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $162.40.
Omnicell Stock Down 0.9 %
Shares of OMCL Stock traded down $1.03 during trading on Thursday, reaching $108.20. The company's stock had a trading volume of 191,098 shares, compared to its average volume of 496,607. The business has a fifty day moving average price of $112.23 and a 200-day moving average price of $120.93. The company has a quick ratio of 1.71, a current ratio of 2.11 and a debt-to-equity ratio of 0.52. The company has a market cap of $4.79 billion, a price-to-earnings ratio of 86.06, a price-to-earnings-growth ratio of 3.76 and a beta of 1.04. Omnicell has a one year low of $103.62 and a one year high of $187.29.
Omnicell (NASDAQ:OMCL - Get Rating) last issued its earnings results on Thursday, August 4th. The company reported $0.84 earnings per share for the quarter, missing analysts' consensus estimates of $0.85 by ($0.01). The firm had revenue of $331.39 million for the quarter, compared to analyst estimates of $339.45 million. Omnicell had a return on equity of 10.37% and a net margin of 4.82%. Omnicell's quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.71 earnings per share. Analysts anticipate that Omnicell will post 2.7 earnings per share for the current year.
Insider Buying and Selling
In related news, EVP Scott Peter Seidelmann sold 3,765 shares of the business's stock in a transaction on Thursday, June 16th. The shares were sold at an average price of $110.15, for a total transaction of $414,714.75. Following the transaction, the executive vice president now directly owns 40,789 shares in the company, valued at $4,492,908.35. The sale was disclosed in a filing with the SEC, which is available through this link. 2.76% of the stock is owned by corporate insiders.
